Immune Vulnerabilities of Mutant KRAS in Pancreatic Cancer

T cells engineered with mutant (m)KRAS-specific T cell receptors have already shown early clinical promise, and next-generation mKRAS vaccines are being studied. As this emerging field rapidly develops, scientists suggest that a significant component in ‘drugging KRAS’ may be immunological.